For example, in analyses that cross-classified ER-positive breast cancer patients by either risk classifier, tumor size, and tumor grade, the 10-year absolute risk of breast cancer death was relatively low for tamoxifen-treated patients presenting with small, low-grade tumors in all three MGI+HOXB13:IL17BR or BCI risk groups. This evidence concerns the gene HOXB13 and neoplasm.